panaloko online game
A Malcolm in the Middle Reboot: Yes, No, Maybe, I Don’t Know?
NoneNEW BRITAIN, Conn. (AP) — Devin Haid had 24 points in Cent. Conn. St.'s 84-80 win against Quinnipiac on Saturday. Haid added six rebounds and four steals for the Blue Devils (8-4). Max Frazier scored 17 points and added nine rebounds. Davonte Sweatman had 14 points and shot 5 for 9 (1 for 3 from 3-point range) and 3 of 4 from the free-throw line. The Bobcats (5-7) were led by Amarri Tice, who posted 21 points, 10 rebounds and four steals. Paul Otieno added 13 points and six rebounds for Quinnipiac. Ryan Mabrey also recorded 12 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
Apple’s plans for a Siri evolution keep getting pushed into the future - Digital TrendsNone
Amazon invests another $4 bn in AI firm AnthropicLife on Mars: As Elon Musk envisions colonising Mars, netizens start discussing who will govern
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 MillionNone
While a pronounced hot streak has vaulted the Los Angeles Kings to near the top of a crowded Pacific Division, the New York Rangers are still trying to emerge from a lengthy slump. The Rangers will look to work out the kinks on Saturday afternoon when the teams meet in New York. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Cardlytics reports that card-linked cash-back offers represent a strategic stocking stuffer for smart shoppers navigating the expensive holiday landscape. Click for more. Holiday spending hacks: How to unwrap savings without sacrificing festive cheerNone
Matt Gaetz isn’t returning to Congress. Will he find a new home on MAGA favorite Newsmax?
Small SUVs continued to sell well in Australia throughout 2024, and that meant there were plenty of them for us to review. or signup to continue reading As we continue recapping our 2024, we're compiling the highest-rated cars from across Australia's most popular new car segments into a list to show you what we liked best. We've done mid-sized SUVs and utes so far, which means small SUVs are now up to bat. For this list we've kept it to the sub-$45,000 segment on the VFACTS sales charts, as they're much more approachable for people wanting to simply get behind the wheel. Some of these models have been reviewed on multiple occasions this year, so we've only featured the variant that achieved the highest rating. Prices are based on each manufacturer's configurators for a Victorian postcode, which should provide a representative estimate of what the average Australian buyer will end up paying. Our top sub-$45,000 small SUV for 2024 was the , which senior contributor Matt Campbell awarded a score of 8.4. That score was for the base GX Hybrid, which we said offered exceptional value, space and efficiency underneath a barebones presentation. "Basic but brilliant" was the term used to sum up the Corolla Cross, and our rating reflects that. It achieved an excellent fuel efficiency of just 4.3L/100km during our test, and with top-notch safety and interior space ratings we deemed it to be properly fit for purpose. We didn't like how it's fitted with halogen daytime running lights instead of LEDs. That lead us to suggest the step up to the GXL for an extra $4000-odd was worth it, especially when you consider this base spec is already more than $40,000 drive-away. Still, we found it to be a well-considered small SUV that can comfortably get the job done in a no-frills manner. The received a facelift this year, and our all-encompassing review of the new two-model range by marketplace journalist Josh Nevett listed a score of 8.4. It was praised for its quality tech upgrades, while it also benefits from packing in big-car practicality into its small-car frame. Better yet, we said it was a great value proposition – especially given the base Select costs just $33,990 drive-away. We gave it high individual scores across the board, headlined by a fit-for-purpose rating of 9 and a safety rating of 8.9. The Kamiq also impressed with its low cost of ownership and fuel efficiency, the latter a product of its two quality engines; turbos with either three or four cylinders. A negative aspect was the Monte Carlo's "polarising" interior design, while we were disappointed that the base-spec Select misses out on adaptive cruise control. As is often a complaint with dual-clutch cars, we also found the Kamiq's DSG unit was clunky at low speed, though it did have solid performance once on the move. As reviewed by marketplace editor James Wong, the scored a respectable 8.2 in March this year. We liked the hybrid Qashqai's seemingly easy performance, something that comes as a result of Nissan's unique electric motor-internal combustion engine it has over other traditional hybrids. That gives it a more electric vehicle (EV) feel, though a normal engine can still be heard. That also contributes to its refined on-road characteristics, as it's mostly quiet at low speeds and generally very smooth. Nissan backs up those traits with an upmarket interior that punches above the Qashqai's paygrade. It wasn't all positive though. We don't like how the e-Power Qashqai is only available in one top-spec Ti variant, as it seems to push it out of the realm of a lot of hybrid buyers. It's also considerably more expensive than the non-hybrid equivalent. We also felt its ride could be somewhat firm on occasion, but none of that was enough to detract from an otherwise solid Toyota hybrid rival. We've published a handful of reviews for small SUV this year, but it was senior contributor Matt Campbell's review of the Style that scored the highest at 8.2. The Style is one rung up from the bottom of the T-Roc range, and we liked it for its easy driving characteristics and its well-laid out cabin. It's also a considerable improvement on the features list compared to the base CityLife without being too much more expensive. We felt it was nicely fit for purpose, and it scored highly on ride comfort and infotainment technology. Under the bonnet is a simple 1.4-litre four-cylinder turbo sent to the front wheels only, with higher-performance options reserved for more expensive T-Rocs. On the other hand, we felt its eight-speed automatic transmission wasn't quite as sharp as Volkswagen's typical dual-clutch DSG, but that did mean its low-speed drivability was improved. Its second row also isn't terribly large as a result of the small SUV frame, and rough roads can induce a fair bit of cabin noise. Still, we found it to be a solid choice for crossover customers. Honda's smallest SUV entered 2024 off the back of a fresh redesign, and news editor William Stopford found its top-spec variant to be worthy of a score of 8.1 That variant is the e:HEV L, the one hybrid in the range. We liked how refined it appeared to be, and the Magic Seats in its second row proved to be practical in the real world. Its cabin is also well-appointed and spacious, while everything is practical and easy to operate in daily use. Even those coming to the HR-V for the first time will likely find it easy to get settled. It lost marks for its price and lack of a spare wheel, and we really couldn't get past the fact it's only a four-seater. There's enough space for a third seat on the second row, but the lack of a centre seatbelt means it can't legally be used as a seat. While the HR-V may not feel as premium as its ZR-V sibling, there's a lot that it does right to deserve a spot on this list. There were four other small SUVs that were also rated at 8.1, and we feel they deserve a mention too. The final spot on the list above could have easily been taken by the , though the Honda comes first alphabetically. You can read the review of that CX-30 . Our all-encompassing review of the could also sneak in, but because a later review of the specific variant scored 7.9 we decided to give it an honourable mention instead. The scored 8.1 too, but because that was also a broad review of a model we're yet to review in specifics it gets an honourable mention. Like, the new C-HR GR Sport, the outgoing scored 7.6. Finally is the , which scored 8.1 in its standalone review. We've given it an honourable mention because we're yet to get our hands on one to test at home in our usual manner. Content originally sourced from: Advertisement Sign up for our newsletter to stay up to date. We care about the protection of your data. Read our . Advertisement
In 2020, a conspiracy theory spread across social media claiming that online home goods retailer Wayfair was involved in child trafficking . People claimed that odd pricing and certain product names were evidence of the theory. VERIFY reader Leslie emailed us to ask if Wayfair was ever involved in the sex trafficking of children. THE QUESTION Is Wayfair involved in the sex trafficking of children? THE SOURCES National Center on Sexual Exploitation DeliverFund , a nonprofit intelligence agency that uses technology to help law enforcement fight human trafficking Polaris , organization that operates the U.S. National Human Trafficking hotline Original VERIFY reporting in 2020 Statement from Wayfair to the BBC in 2020 THE ANSWER No, there is no evidence to support the claims that Wayfair was involved in the sex trafficking of children. WHAT WE FOUND When the conspiracy theory first spread in 2020, people on social media pointed to Wayfair products with strange names and disproportionately high prices as proof that the online furniture store was involved in child trafficking. These products included a “Samiyah Storage Cabinet” priced at over $14,000 and a “Duplessis Zodiac Sign Astrological Constellation Personalized Throw Pillow” at $9,999. At the time, people claimed that these products shared the names of girls that were reported missing. The theory followed that the products had high prices because they were fronts for selling the missing girls. Wayfair told the BBC in 2020 that the prices were accurate for the industrial grade cabinets and were the result of a glitch in the case of the pillows. The viral social media posts frequently linked products to girls who were no longer missing. Multiple anti-trafficking groups said the claims were unproven and likely false. “We believe that the accusations being leveled against Wayfair regarding sex trafficking are lacking credibility in significant ways and, in many places, demonstrably false,” the National Center on Sexual Exploitation said at the time. In 2020, VERIFY found that the family of Samara Duplessis, a missing girl purportedly linked to the overpriced pillows, reported she was back home a couple of months before the Wayfair conspiracy became widespread. When VERIFY searched Wayfair for “Duplessis” products in 2020, we found the name attached to a number of different items that were considerably less expensive than the pillow. When VERIFY searched Wayfair’s site again on Dec. 2, 2024, we found it’s using the “Duplessis” name for at least one product, a rug selling for $144.99 , years after the missing girl was found. As for the reference to the cabinets in the original rumors, people claimed that there was a missing teenager from Ohio named Samiyah, too. But VERIFY was unable to find any evidence that a girl by that name was missing, and a teenager some people believed to be Samiyah refuted that she was missing in a video posted to her Facebook account. Wayfair told the BBC in 2020 that the expensive cabinets were “industrial size,” meant for business or commercial use and that the $14,000 price point was accurate. “We have temporarily removed the products from our site to rename them and to provide a more in-depth description and photos that accurately depict the product to clarify the price point,” Wayfair told the BBC in 2020. Another example of a missing teenager’s name possibly matching a Wayfair product was Mary Durrett to a Durrett coffee table. But she went missing in 2017 and was found safe two days after she was first reported missing. The claim connecting her to the coffee table listing was posted three years later. Many anti-trafficking organizations addressed the rumors in 2020. They all said the claims lacked credibility. “We identified early on that this was a likely hoax or a case of overexuberance by someone who did not have the expertise and data-driven approach that DeliverFund has,” Michael Fullilove, chief of operations for DeliverFund , a nonprofit intelligence agency that uses technology to help law enforcement fight human trafficking, said in 2020. “Based on the original source of the information, we were able to use open source intelligence techniques to determine that it was highly unlikely that the trafficking of children was taking place through the sale of expensive items on Wayfair,” Fullilove said. Polaris , which operates the U.S. National Human Trafficking Hotline, said the claims were unsubstantiated and did more harm than good. People overwhelmed the hotline to make reports related to the conspiracy, increasing wait times and potentially denying trafficking victims from reaching the hotline. The theory also resulted in harassment and privacy intrusions of people mistakenly believed to be victims, as well as broad sharing of online sexual abuse material of real victims never connected to the Wayfair conspiracy, Polaris said. Polaris pointed out that trafficking is rarely perpetrated by a total stranger who kidnaps children and is instead usually perpetrated by people the victims know or even love and trust. Scenarios where the trafficker locks up or imprisons the victim with literal shackles make up a minority of trafficking cases despite it being the common public perception of trafficking, the National Center on Sexual Exploitation said. Traffickers usually groom their victims and keep them captive through forms of psychological abuse, manipulation and coercion that can be difficult to identify. There are real cases in which sex trafficking is perpetrated online, usually through prostitution sites and pornography websites, according to the National Center on Sexual Exploitation. The National Center on Sexual Exploitation said in 2020 that traffickers were increasingly using “popular social media apps such as Instagram, Snapchat and TikTok to identify, groom and exploit children in the online space.” Anti-trafficking organizations say that sharing viral, unsubstantiated trafficking rumors online is generally unhelpful to trafficking victims. What’s more helpful, these organizations say , is to learn how to identify real, common cases of trafficking to spot victims who need help. VERIFY reached out to Wayfair for comment but did not receive a response by the time of publication. The VERIFY team works to separate fact from fiction so that you can understand what is true and false. Please consider subscribing to our daily newsletter , text alerts and our YouTube channel . You can also follow us on Snapchat , Instagram , Facebook and TikTok . Learn More » Follow Us Want something VERIFIED? Text: 202-410-8808West Ham 0–5 Liverpool, Premier League 2024–25: Mohamed Salah, Trent Alexander-Arnold, Luis Diaz and Others Score As Merseysiders Thrash the Hammers To Maintain EPL Lead